Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veritas In Silico Inc. ( (JP:130A) ) just unveiled an announcement.
Veritas In Silico Inc. announced that its patent for a method of screening compounds to control RNA function has been approved by the United States Patent and Trademark Office. This patent, which is integral to the company’s drug discovery platform, has already been granted in Japan and Europe. The U.S. approval enhances the company’s international patent portfolio, reinforcing its technological superiority and supporting its global research collaborations.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the biotechnology industry, focusing on drug discovery through its proprietary platform, ibVIS®. The company is listed on the TSE Growth market and is involved in the development of innovative methods for controlling RNA function.
Average Trading Volume: 78,778
Technical Sentiment Signal: Sell
For an in-depth examination of 130A stock, go to TipRanks’ Overview page.